{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:58:08Z","timestamp":1788044288177,"version":"build-2784847793"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although both cinacalcet and etelcalcetide are calcimimetics that directly inhibit parathyroid hormone (PTH) secretion by activating the calcium (Ca)-sensing receptor (CaSR), their binding sites are different. We report a first case of a hemodialysis (HD) patient with secondary hyperparathyroidism (SHPT), in whom cinacalcet, but not etelcalcetide, could reduce serum intact PTH (i-PTH) levels. A HD patient received total parathyroidectomy (PTx) with auto-transplantation 16\u00a0years earlier. Due to SHPT relapse, cinacalcet was started at 7\u00a0years after PTx. His i-PTH levels had been controlled with both 75\u2013100\u00a0mg of cinacalcet and 4.5\u00a0\u03bcg\/week of calcitriol for a year before switching from cinacalcet to etelcalcetide. At 1\u00a0month following the switch, his serum i-PTH level increased to 716\u00a0pg\/mL. The dose of etelcalcetide was gradually increased and finally reached the maximal dose of 45\u00a0mg\/week. Because even the maximal dose of etelcalcetide for\u2009&gt;\u20094\u00a0months did not reduce his serum i-PTH levels to\u2009&lt;\u2009700\u00a0pg\/mL, etelcalcetide was switched to 50\u00a0mg\/day of cinacalcet, which reduced the levels to 208\u00a0pg\/mL at 2\u00a0months after the switch. Genomic sequencing test using whole blood revealed no mutation in the portion including Cys 482 of CaSR gene. The patient was resistant to etelcalcetide treatment but not to cinacalcet, suggesting the possibility that the enlarged parathyroid gland has some change in the portion including Cys 482 in the CaSR gene. Therefore, considering the possibility of etelcalcetide resistance during SHPT treatment should be kept in mind.<\/jats:p>","DOI":"10.1007\/s13730-021-00664-0","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T08:02:58Z","timestamp":1637136178000},"page":"254-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride"],"prefix":"10.1007","volume":"11","author":[{"given":"Hironori","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Tokumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Anayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigekazu","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"664_CR1","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317:156\u201364.","journal-title":"JAMA"},{"key":"664_CR2","doi-asserted-by":"crossref","unstructured":"Fukagawa M, Shimazaki R, Akizawa T, Evocalcet Study Group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 2018;94:818\u201325.","DOI":"10.1016\/j.kint.2018.05.013"},{"issue":"6 Pt 1","key":"664_CR3","first-page":"E680","volume":"251","author":"P D'Amour","year":"1986","unstructured":"D\u2019Amour P, Labelle F, Lecavalier L, Plourde V, Harvey D. Influence of serum Ca concentration on circulating molecular forms of PTH in three specie. Am J Physiol. 1986;251(6 Pt 1):E680\u20137.","journal-title":"Am J Physiol"},{"key":"664_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ki.1989.305","volume":"36","author":"R Dunlay","year":"1989","unstructured":"Dunlay R, Rodrigues M, Felsenfeld AJ, Llach F. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int. 1989;36:1093\u20138.","journal-title":"Kidney Int"},{"key":"664_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1124\/mol.115.098392","volume":"88","author":"ST Alexander","year":"2015","unstructured":"Alexander ST, Hunter T, Walter S, Dong J, Maclean D, Baruch A, Subramanian R, Tomlinson JE. Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol Pharmacol. 2015;88:853\u201365.","journal-title":"Mol Pharmacol"},{"key":"664_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1124\/dmd.115.068007","volume":"44","author":"R Subramanian","year":"2016","unstructured":"Subramanian R, Zhu X, Kerr SJ, Esmay JD, Louie SW, Edson KZ, Walter S, Fitzsimmons M, Wagner M, Soto M, Pham R, Wilson SF, Skiles GL. Nonclinical pharmacokinetics, disposition, and drug-drug interaction potential of a novel d-amino acid peptide agonist of the calcium-sensing receptor AMG 416 (Etelcalcetide). Drug Metab Dispos. 2016;44:1319\u201331.","journal-title":"Drug Metab Dispos"},{"key":"664_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000350211","volume":"37","author":"K Sumida","year":"2013","unstructured":"Sumida K, Nakamura M, Ubara Y, Marui Y, Tanaka K, Takaichi K, Tomikawa S, Inoshita N, Ohashi K. Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients. Am J Nephrol. 2013;37:405\u201312.","journal-title":"Am J Nephrol"},{"key":"664_CR8","doi-asserted-by":"publisher","first-page":"F605","DOI":"10.1152\/ajprenal.90272.2008","volume":"296","author":"FJ Mendoza","year":"2009","unstructured":"Mendoza FJ, Lopez I, Canalejo R, Almaden Y, Martin D, Aguilera-Tejero E, Rodriguez M. Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats. Am J Physiol Renal Physiol. 2009;296:F605\u201313.","journal-title":"Am J Physiol Renal Physiol"},{"key":"664_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/jpet.113.204834","volume":"346","author":"S Walter","year":"2013","unstructured":"Walter S, Baruch A, Dong J, Tomlinson JE, Alexander ST, Janes J, Hunter T, Yin Q, Maclean D, Bell G, Mendel DB, Johnson RM, Karim F. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther. 2013;346:229\u201340.","journal-title":"J Pharmacol Exp Ther"},{"key":"664_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/01213011-200501000-00005","volume":"15","author":"HM Rothe","year":"2005","unstructured":"Rothe HM, Shapiro WB, Sun WY, Chou SY. Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl. Pharmacogenet Genomics. 2005;15:29\u201334.","journal-title":"Pharmacogenet Genomics"},{"key":"664_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00000658-200201000-00013","volume":"235","author":"FF Chou","year":"2002","unstructured":"Chou FF, Lee CH, Chen HY, Chen JB, Hsu KT, Sheen-Chen SM. Persistent and recurrent hyperparathyroidism after total parathyroidectomy with autotransplantation. Ann Surg. 2002;235:99\u2013104.","journal-title":"Ann Surg"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-021-00664-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-021-00664-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-021-00664-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T13:20:18Z","timestamp":1651497618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-021-00664-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["664"],"URL":"https:\/\/doi.org\/10.1007\/s13730-021-00664-0","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"11 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Nakamura has received the lecture fee from Astellas, Bayer, and Kyowa Kirin Co., Ltd. Dr. Tokumoto received the lecture fee from Bayer Yakuhin, Kissei Pharmaceutical Co., Ono Pharmaceutical Co., Sanwa Kagaku Kenkyusho Co. and Kyowa Kirin Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the patient for publication of this case report, CT images and genetic analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}